24 January 2022
: Case report 
Prolonged Cefepime-Induced Neurotoxicity in a Patient with End-Stage Renal Disease
Unusual clinical course, Adverse events of drug therapy, Clinical situation which can not be reproduced for ethical reasons
Dorothy Dao Nguyen1ADEF*, Samuel Lai1DEDOI: 10.12659/AJCR.934083
Am J Case Rep 2022; 23:e934083
Table 1. Susceptibilities from patient’s blood cultures growing extended-spectrum beta-lactamase Escherichia coli., with associated MIC.
| Antibiotic | VITEK MIC (mcg/mL) | Susceptibility |
|---|---|---|
| Amikacin | 4 | Susceptible |
| Ampicillin | ≥32 | Resistant |
| Ampicillin/Sulbactam | ≥32 | Resistant |
| Cefazolin | ≥8 | Resistant |
| Cefepime | 2 | Susceptible |
| Ceftriaxone | ≥64 | Resistant |
| Cefuroxime | ≥64 | Resistant |
| Ciprofloxacin | ≥4 | Resistant |
| Gentamicin | ≥16 | Resistant |
| Levofloxacin | ≥8 | Resistant |
| Piperacillin/Tazobactam | 16 | Susceptible |
| Tobramycin | ≥16 | Resistant |
| Trimethoprim/Sulfamethoxazole | ≤20 | Susceptible |
| MIC – minimum inhibitory concentration. | ||